Karyopharm Therapeutics Liabilities 2024

Karyopharm Therapeutics Aktienanalyse

What does Karyopharm Therapeutics do?

Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts. The company focuses its research and development on the use of selective inhibitors of nuclear export (SINE) for the treatment of cancer and inflammatory diseases. Karyopharm Therapeutics has been active in the field of biotechnology research since 2010. Karyopharm Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Karyopharm Therapeutics's Liabilities

Karyopharm Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Karyopharm Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Karyopharm Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Karyopharm Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Karyopharm Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Karyopharm Therapeutics Stock

What is the level of liabilities of Karyopharm Therapeutics this year?

Karyopharm Therapeutics has a debt balance of 376.64 M USD this year.

What were the liabilities of Karyopharm Therapeutics compared to the previous year?

The liabilities of Karyopharm Therapeutics have increased by 0.49% increased compared to the previous year.

What are the consequences of high debt for investors of Karyopharm Therapeutics?

High liabilities can pose a risk for investors of Karyopharm Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Karyopharm Therapeutics?

Low liabilities mean that Karyopharm Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Karyopharm Therapeutics affect the company?

An increase in liabilities of Karyopharm Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Karyopharm Therapeutics affect the company?

A decrease in the liabilities of Karyopharm Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Karyopharm Therapeutics?

Some factors that can influence the liabilities of Karyopharm Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Karyopharm Therapeutics so important for investors?

The liabilities of Karyopharm Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Karyopharm Therapeutics take to modify the liabilities?

To change its liabilities, Karyopharm Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Karyopharm Therapeutics pay?

Over the past 12 months, Karyopharm Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karyopharm Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Karyopharm Therapeutics?

The current dividend yield of Karyopharm Therapeutics is .

When does Karyopharm Therapeutics pay dividends?

Karyopharm Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karyopharm Therapeutics?

Karyopharm Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Karyopharm Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karyopharm Therapeutics located?

Karyopharm Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karyopharm Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karyopharm Therapeutics from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Karyopharm Therapeutics pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Karyopharm Therapeutics in the year 2023?

In the year 2023, Karyopharm Therapeutics distributed 0 USD as dividends.

In which currency does Karyopharm Therapeutics pay out the dividend?

The dividends of Karyopharm Therapeutics are distributed in USD.